ArticleAmerican heart journal plus : cardiology research and practice2025
Cholesterol crystal embolization induced kidney disease.
Article in American heart journal plus : cardiology research and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Editorial for the Special Issue on Cholesterol Crystal Embolization.American heart journal plus : cardiology research and practice · 2026Article
- Fulminant cholesterol crystal embolism syndrome triggered by Vein of Marshall ethanol infusion: a case report.BMC cardiovascular disorders · 2026Article
- Hemodialysis and high-dose steroids can salvage renal function in cholesterol crystal embolization: Acute kidney injury secondary to microemboli to a solitary kidney during aortic endovascular aneurysm repair.Journal of vascular surgery cases and innovative techniques · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholesterol crystal embolization (CCE) results from the release of cholesterol crystals from ruptured atherosclerotic plaques into circulation, resulting in the occlusion of small arteries and arterioles in various organs. Ischemia triggers a systemic inflammatory response resulting in vascular obstruction and organ dysfunction. Kidneys are often involved because of the proximity to the aorta and CCE in the kidneys can result in acute, sub-acute, or chronic kidney disease. There are many known risk factors for renal involvement of CCE, including iatrogenic and spontaneous causes. The pathophysiology of CCE includes complex pathways that lead to acute and chronic effects that can have direct deleterious effects on the kidney. The diagnosis entails numerous lab studies and potential need for tissue biopsy. Treatment is often supportive but can also include more novel therapies. This paper reviews the pathophysiology, clinical manifestations, diagnostic approaches, and management strategies for CCE affecting the kidneys.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.